Anavex Life Sciences Corp expected to post a loss of 17 cents a share - Earnings Preview

Anavex Life Sciences

04/08/2023 19:36

* Anavex Life Sciences Corp  AVXL.OQ   AVXL.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 8. 
    * 
    * ​Refinitiv's mean analyst estimate for Anavex Life
Sciences Corp
is for a loss of 17 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Anavex Life
Sciences Corp is $47​, above​ its last closing price of $8.30.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.19       -0.19      -0.17     Beat    8.9
 Dec. 31 2023  -0.20       -0.19      -0.17     Beat    10.5
 Sep. 30 2022  -0.16       -0.16      -0.18     Missed  -11.1​
 Jun. 30 2022  -0.15       -0.15      -0.16     Missed  -5.3
 ​​Mar.        -0.17       -0.17      -0.14     Beat    16.4
 31 2022                                                
 Dec. 31 2021  -0.15       -0.15      -0.14     Beat    9.7​
 Sep. 30 2021  -0.16       -0.15      -0.15     Met     -2.3
 Jun. 30 2021  -0.13       -0.13      -0.14     Missed  -4.5
 This summary was machine generated August 4 at 18:36 GMT.  All
figures in US dollars  unless otherwise stated